Perceive Pharma, a San Francisco, CA-based pharmaceutical company advancing novel small molecule therapeutics in ophthalmology, raised $15M in Series A funding.
The round was led by Deerfield Management, Johnson & Johnson, Braidwell LP, GV, the Retinal Degeneration Fund, and Catalio Capital Management, LP.
Led by CEO K. Angela Macfarlane, Perceive Pharma is advancing novel small molecule neuroprotective therapeutics, with lead pipeline programs in glaucoma and other ophthalmic diseases. The company is focused on the neuroprotective pathways first elucidated in a genomic screening by co-founders Drs. Don Zack and Derek Welsbie, who further collaborated with a key industry partner to position Perceive Pharma with a library of neuroprotective drug candidates, including its lead therapeutic candidate, PBI-671.
Series A proceeds will advance the development of first-in-class therapies to prevent vision loss in glaucoma, and additional undisclosed disease areas.
Spun out from Perceive Biotherapeutics, Inc., Perceive Pharma also announced that Carol Gallagher, Pharm.D. has joined the company’s Board of Directors as an independent director.
FinSMEs
18/02/2025